ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer (opens in a new tab)

medicalxpress.com · 2026-10-23

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

17 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail

The story

ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer

medicalxpress.com · 2026-10-23

The story’s checkable claims.

Read the original story

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

Cited as backgroundpresented as earlier work
https://medicalxpress.com/news/2026-06-rason-inhibitor-median-survival-patients.html
Where the story links (opens in a new tab)

Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Reading mode

Scan verdicts. Open evidence only when needed.

Claim 1 of 3Not checkedA new analysis of a phase 3 clinical trial found that daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 3Not checkedThe findings, presented at the European Society for Medical Oncology (ESMO) Congress by Dr. Zev Wainberg, build on earlier results from the RASolute 302 trial, which showed a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy in previously treated metastatic pancreatic cancer.View evidenceHide evidence

As statedmedian overall survival 13.2 months vs 6.7 months

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 3Not checkedThe latest analysis suggests the survival benefit was consistent across different RAS mutation subsets, different chemotherapy regimens, and prior-treatment settings, but some subgroup sizes were small and further follow-up is needed.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results